GlassScriptPhysician profile
Michelle Siew
NPI 1336710656
$1,100.67
in general payments reported to CMS, 2019-2025
15 companies · $90.87 in 2025
The $90.87 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $113 · 2022: $473 · 2023: $197 · 2024: $227 · 2025: $90.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $514.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $143.89 | 2021-2024 | Opdivo, Camzyos |
| Gilead Sciences, INC. | $135.35 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.96 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $118.95 | 2022-2024 | |
| Boston Scientific Corporation | $114.01 | 2022 | |
| Abbvie INC. | $104.11 | 2023-2025 | Botox |
| Novo Nordisk INC | $85.77 | 2024 | Ozempic, Rybelsus |
| Alexion Pharmaceuticals, INC. | $70.21 | 2022-2023 | Ultomiris |
| Glaxosmithkline, LLC. | $42.86 | 2022-2023 | Trelegy Ellipta |
| Incyte Corporation | $37.22 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $34.23 | 2022 | |
| Karyopharm Therapeutics INC. | $31.91 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.02 | 2024 | Entyvio |
| Actelion Pharmaceuticals US, INC. | $20.82 | 2025 | Uptravi, Opsumit |
| Alcresta Therapeutics, INC. | $16.36 | 2023 | Relizorb |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Siew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.